Work

Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib: A California Cancer Consortium Phase II trial (NCI 8698).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.8015

Authors: Primo Lara, Jeff Longmate, Philip C. Mack, Karen Kelly, Mark A. Socinski, Ravi Salgia, Barbara Jennifer Gitlitz, Tianhong Li, Marianna Koczywas, Karen L. Reckamp, David R. Gandara

Institutions: University of California Davis Medical Center, City Of Hope National Medical Center, City of Hope, UC Davis Comprehensive Cancer Center, University of Pittsburgh, University of Chicago, USC Norris Comprehensive Cancer Center, University of California, Davis

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603713440

Cites:

Cited by: 8

Related to: 10